Cargando…

Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment

Requirements of large numbers of transferred T cells and various immunosuppressive factors and cells in the tumor microenvironment limit the applications of adoptive T cells therapy (ACT) in clinic. Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of imm...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuang, Hui-Yen, Chang, Ya-Fang, Liu, Ren-Shyan, Hwang, Jeng-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198194/
https://www.ncbi.nlm.nih.gov/pubmed/25333973
http://dx.doi.org/10.1371/journal.pone.0109992
_version_ 1782339707515961344
author Chuang, Hui-Yen
Chang, Ya-Fang
Liu, Ren-Shyan
Hwang, Jeng-Jong
author_facet Chuang, Hui-Yen
Chang, Ya-Fang
Liu, Ren-Shyan
Hwang, Jeng-Jong
author_sort Chuang, Hui-Yen
collection PubMed
description Requirements of large numbers of transferred T cells and various immunosuppressive factors and cells in the tumor microenvironment limit the applications of adoptive T cells therapy (ACT) in clinic. Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of immunosuppressive agents when proper dosage is used, and combined with immunotherapy often results in better treatment outcomes than monotherapy. Controversial immunomodulation effects of sorafenib, a multi-kinases inhibitor, at high and low doses have been reported in several types of cancer. However, what is the range of the low-dose sorafenib will influence the host immunity and responses of ACT is still ambiguous. Here we used a well-established E.G7/OT-1 murine model to understand the effects of serial low doses of sorafenib on both tumor microenvironment and transferred CD8+ T cells and the underlying mechanisms. Sorafenib lowered the expressions of immunosuppressive factors, and enhanced functions and migrations of transferred CD8+ T cells through inhibition of STAT3 and other immunosuppressive factors. CD8+ T cells were transduced with granzyme B promoter for driving imaging reporters to visualize the activation and distribution of transferred CD8+ T cells prior to adoptive transfer. Better activations of CD8+ T cells and tumor inhibitions were found in the combinational group compared with CD8+ T cells or sorafenib alone groups. Not only immunosuppressive factors but myeloid derived suppressive cells (MDSCs) and regulatory T cells (Tregs) were decreased in sorafenib-treated group, indicating that augmentation of tumor inhibition and function of CD8+ T cells by serial low doses of sorafenib were via reversing the immunosuppressive microenvironment. These results revealed that the tumor inhibitions of sorafenib not only through eradicating tumor cells but modifying tumor microenvironment, which helps outcomes of ACT significantly.
format Online
Article
Text
id pubmed-4198194
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41981942014-10-21 Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment Chuang, Hui-Yen Chang, Ya-Fang Liu, Ren-Shyan Hwang, Jeng-Jong PLoS One Research Article Requirements of large numbers of transferred T cells and various immunosuppressive factors and cells in the tumor microenvironment limit the applications of adoptive T cells therapy (ACT) in clinic. Accumulating evidences show that chemotherapeutic drugs could act as immune supportive instead of immunosuppressive agents when proper dosage is used, and combined with immunotherapy often results in better treatment outcomes than monotherapy. Controversial immunomodulation effects of sorafenib, a multi-kinases inhibitor, at high and low doses have been reported in several types of cancer. However, what is the range of the low-dose sorafenib will influence the host immunity and responses of ACT is still ambiguous. Here we used a well-established E.G7/OT-1 murine model to understand the effects of serial low doses of sorafenib on both tumor microenvironment and transferred CD8+ T cells and the underlying mechanisms. Sorafenib lowered the expressions of immunosuppressive factors, and enhanced functions and migrations of transferred CD8+ T cells through inhibition of STAT3 and other immunosuppressive factors. CD8+ T cells were transduced with granzyme B promoter for driving imaging reporters to visualize the activation and distribution of transferred CD8+ T cells prior to adoptive transfer. Better activations of CD8+ T cells and tumor inhibitions were found in the combinational group compared with CD8+ T cells or sorafenib alone groups. Not only immunosuppressive factors but myeloid derived suppressive cells (MDSCs) and regulatory T cells (Tregs) were decreased in sorafenib-treated group, indicating that augmentation of tumor inhibition and function of CD8+ T cells by serial low doses of sorafenib were via reversing the immunosuppressive microenvironment. These results revealed that the tumor inhibitions of sorafenib not only through eradicating tumor cells but modifying tumor microenvironment, which helps outcomes of ACT significantly. Public Library of Science 2014-10-15 /pmc/articles/PMC4198194/ /pubmed/25333973 http://dx.doi.org/10.1371/journal.pone.0109992 Text en © 2014 Chuang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chuang, Hui-Yen
Chang, Ya-Fang
Liu, Ren-Shyan
Hwang, Jeng-Jong
Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
title Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
title_full Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
title_fullStr Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
title_full_unstemmed Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
title_short Serial Low Doses of Sorafenib Enhance Therapeutic Efficacy of Adoptive T Cell Therapy in a Murine Model by Improving Tumor Microenvironment
title_sort serial low doses of sorafenib enhance therapeutic efficacy of adoptive t cell therapy in a murine model by improving tumor microenvironment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4198194/
https://www.ncbi.nlm.nih.gov/pubmed/25333973
http://dx.doi.org/10.1371/journal.pone.0109992
work_keys_str_mv AT chuanghuiyen seriallowdosesofsorafenibenhancetherapeuticefficacyofadoptivetcelltherapyinamurinemodelbyimprovingtumormicroenvironment
AT changyafang seriallowdosesofsorafenibenhancetherapeuticefficacyofadoptivetcelltherapyinamurinemodelbyimprovingtumormicroenvironment
AT liurenshyan seriallowdosesofsorafenibenhancetherapeuticefficacyofadoptivetcelltherapyinamurinemodelbyimprovingtumormicroenvironment
AT hwangjengjong seriallowdosesofsorafenibenhancetherapeuticefficacyofadoptivetcelltherapyinamurinemodelbyimprovingtumormicroenvironment